Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EML4 | Q9HC35 | 5/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.32 |
| ▸ | RET | P07949 | 5/20 | 0.32 |
| ▸ | ROS1 | P08922 | 5/20 | 0.32 |
| ▸ | FLT3 | P36888 | 5/20 | 0.32 |
| ▸ | SYK | P43405 | 2/20 | 0.31 |
| ▸ | LCK | P06239 | 3/20 | 0.30 |
| ▸ | JAK3 | P52333 | 3/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30205929 | 0.92 | — | — | |
| SCHEMBL30205605 | 0.90 | CDK1 (0.34) | EML4ALKRETROS1FLT3 | |
| SCHEMBL31195426 | 0.90 | CDK1 (0.34) | EML4ALKRETROS1FLT3 | |
| SCHEMBL24945000 | 0.90 | CDK1 (0.34) | EML4ALKRETROS1FLT3 | |
| SCHEMBL30205547 | 0.89 | EML4 (0.31) | EML4ALKSYKLCKJAK3 | |
| SCHEMBL29173290 | 0.89 | MLKL (0.37) | EML4ALKRETROS1FLT3 | |
| SCHEMBL24944970 | 0.85 | LCK (0.40) | EML4ALKRETROS1FLT3 | |
| SCHEMBL24943828 | 0.85 | CDK2 (0.37) | SYKLCKJAK3BTK | |
| SCHEMBL30206306 | 0.84 | EML4 (0.33) | EML4ALKRETROS1FLT3 | |
| SCHEMBL24943847 | 0.84 | EML4 (0.32) | EML4ALKRETROS1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | claimed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | claimed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | claimed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |